FDA approves Imbruvica for rare blood cancer

18 Nov 2013 9:15 PM | Lori Aubrey (Administrator)

Second drug with breakthrough therapy designation to receive FDA approval


November 13, 2013

The U.S. Food and Drug Administration approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.

MCL is a rare form of non-Hodgkin lymphoma and represents about 6 percent of all non-Hodgkin lymphoma cases in the United States. By the time MCL is diagnosed, it usually has already spread to the lymph nodes, bone marrow and other organs.

Imbruvica is intended for patients with MCL who have received at least one prior therapy. It works by inhibiting the enzyme needed by the cancer to multiply and spread. Imbruvica is the third drug approved to treat MCL. Velcade (2006) and Revlimid (2013) are also approved to treat the disease.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm374761.htm

Comments

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software